

Title: Open Science Policy

SOP No.: TRIDENT_Policies_OSP_V2.0

Date: 17 March 2025

Last updated: 9 Jan 2026

Created for TRIDENT, by Dr. Richard Gold (Open Science Lead), Dr. Sriram Jayabal (Research Program Director), and Sarah Brennan (Operations Director).

Open Science Policy

What is TRIDENT?

TRIDENT (the **T**ranslational Initiative to **DE**-risk **NeuroTherapeutics**) is a one-stop-shop pre-clinical evaluation platform that combines three integrated model systems, i.e., induced pluripotent stem cells (iPSCs) & organoids, mice, and marmosets, to test a drug's likely effect on human cognition. The platform provides drug developers with a unique, revolutionary way to determine whether drugs are likely to treat cognitive degeneration in humans, maximizing the predictive validity of their treatments in human clinical trials. TRIDENT standardizes the use of pre-clinical brain imaging and humanized cognitive behavioral testing in animal models, as well as permitting sex-based assessment and testing at multiple sites. TRIDENT aims to dramatically improve the odds of success in clinical trials by de-risking the neurotherapeutics at the very earliest stage possible, i.e., at the pre-clinical stage of drug development.

TRIDENT is a multi-site platform distributed across four major institutions in Canada: Western University, McGill University, the University of Toronto, and the Center for Addiction and Mental Health. TRIDENT and its members advocate and practice open science and transparency at every stage of their research while evaluating neurotherapeutics for external partners, and this is governed by the underlying policy below.

TRIDENT Open Science Policy

Through the practice of its Open Science principles, TRIDENT promotes transparency in the pre-clinical stage of the drug development process. This transparency aims to accelerate the discovery of effective cures and treatments for brain diseases by fostering rapid access to new findings, cohesion, long-term sustainability, and synergy between its transdisciplinary teams of researchers and external partners, including the biotech and pharmaceutical industries. All partners shall be informed and agree to the TRIDENT's Open Science Principles before the TRIDENT platform can evaluate any therapeutic of their interest.

Five key principles make up TRIDENT's open science policy

Principle 1. Public release of data and other scientific resources

TRIDENT and its members will publish open-access articles, including depositing them in pre-print servers. It will render all positive and negative numerical data, models, data sources, materials, reagents, algorithms, software, and other scientific resources publicly available no later than: (i) the publication date of the first article that relies on these data or resources; or (ii) if there is no accompanying article, as soon as the data is validated in accordance with standard scientific practice.



Principle 2. External research partnerships

All publications, data, and scientific resources generated through research partnerships –whether with commercial, philanthropic, or public sector actors – are to be released publicly as set out in Principle 1. If there is a contractual embargo period (6 months and, in exceptional circumstances, up to a year after the data is available to the research partner) with the external partner, the release of project data to the public will occur at the later of: (i) the normal publication date; or (ii) immediately after the embargo period.

Principle 3. Research materials and tools

TRIDENT will make its research materials and tools available to the public at cost so as to ensure that TRIDENT is self-sustaining. Where the materials are in limited supply, TRIDENT will make them available in a way that maximizes scientific and health outcomes.

Principle 4. Intellectual property

TRIDENT aims to serve the public by accelerating research and by providing a pre-clinical testing platform through which drug candidates can be thoroughly and effectively tested. As a result, neither TRIDENT nor its researchers will apply for or agree to be listed as an inventor in any patent application for therapeutics. Should TRIDENT or its researchers be included, contrary to the above, on any patent application or patent, it/they will promptly dedicate their interest in the application or patent to the public. Nothing shall prevent external partners from applying for patent rights as long as such applications do not rely on non-public data or findings conducted by TRIDENT or its researchers.

Principle 5. TRIDENT member autonomy

TRIDENT supports the autonomy of its stakeholders, including but not limited to all its members, such as researchers, staff, trainees, and external partners and stakeholders, by recognizing their right to decline to participate in research and associated activities under its Open Science framework provided that they do not act on behalf of TRIDENT or using funds provided by TRIDENT. However, TRIDENT will not support, pay for, or participate in activities that deviate from the above Principles.

Last updated: Jan 09, 2026

